US FDA Finally Backs Minimal Residual Disease Endpoint For Accelerated Approval In Myeloma

 
• By Manas Mishra
  
The draft guidance emerged after a 2024 advisory committee meeting on the subject. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from United States